COA KVR-2026-AC5545 matches Kovera Labs's public record. So this test doesn't rest on our review alone — the lab confirms it too.
QFUZCV2Label 30 mg · Lab measured 33.18 mg
111% of label, basis not stated — shown as printed. Reconstituted with 2 mL, a 50-unit draw holds 8.3 mg using the measured mass, against 7.5 mg on the label — 11% more.
One vial from this lot was weighed by the laboratory, not yours. This page reports what the certificate says; it does not recommend a dose.
| Report number | KVR-2026-AC5545 |
|---|---|
| Portal lookup | ✓ Lab-verified |
| Checked | 26 Aug 2026date taken from the record, not from a logged check |
| Checked by | Peptigrity staff, against the lab's portal |
| PDF vs portal | Kovera Labs's portal shows validity only |
| Weight | Counts as one lab test |
Independent HPLC purity analysis of Tirzepatide, performed by Kovera Labs on July 21, 2026. Reported purity: 99.332%. Net content: 33.18 mg against 30 mg labeled (111% of label). Tested content exceeds the labeled amount by 11%. Endotoxins: Pass (≤0.5 EU/mL). Heavy metals: Arsenic, Cadmium, Lead, Mercury — all Negative. Batch TZ30-072026-001. Sample source: shop-provided. Certificate of analysis attached.
Submit your third-party lab test to help the community verify purity claims. Every report is reviewed before publication.
Community discussion